Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-Institution Study of Docetaxel and Doxorubicin as Induction Therapy Followed by Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support for Women With Metastatic Breast Cancer

NCT00004906 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT00004906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00004906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-Institution Study of Docetaxel and Doxorubicin as Induction Therapy Followed by Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support for Women With Metastatic Breast Cancer
Lead sponsor
Hackensack Meridian Health
Phase
Phase 2
Overall status
Completed
Start date
October 31, 1999
Completion date
June 30, 2001
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer